Exercise for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Small Cell Lung CancerExercise - Behavioral
Eligibility
50 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether muscle disuse may be a factor in muscle loss for individuals with cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 3 Secondary · Reporting Duration: Difference between the change in the exercised and non-exercised leg from baseline to 8 weeks

Week 8
Cross-sectional area of skeletal muscle fibers
Mitochondrial content
Mitochondrial function
Single muscle fiber contractile function
Whole muscle isokinetic function
Whole muscle isometric function
Whole muscle size

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Exercise
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Exercise · No Placebo Group · N/A

Exercise
Behavioral
Experimental Group · 1 Intervention: Exercise · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~760

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: difference between the change in the exercised and non-exercised leg from baseline to 8 weeks

Who is running the clinical trial?

University of VermontLead Sponsor
254 Previous Clinical Trials
3,742,797 Total Patients Enrolled
University of South CarolinaOTHER
177 Previous Clinical Trials
93,438 Total Patients Enrolled
Michael J. Toth, Ph.D.1.02 ReviewsPrincipal Investigator - University of Vermont
University of Vermont
2 Previous Clinical Trials
60 Total Patients Enrolled

Eligibility Criteria

Age 50 - 75 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: